BPI-002

About BeyondSpring

BeyondSpring is dedicated to developing novel cancer treatments, with its core technology platform based on the small-molecule drug plinabulin, a selective immunomodulating microtubule-binding agent. The company's most advanced program is plinabulin for the prevention of chemotherapy-induced neutropenia (CIN), which has undergone Phase 3 clinical trials. BeyondSpring's strategy involves leveraging plinabulin's dual mechanism of action—protecting bone marrow and activating T-cells—to improve outcomes in cancer care and expand into broader immuno-oncology applications.

Therapeutic Areas

Other Undisclosed Oncology Target Drugs